We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00028145
Recruitment Status : Completed
First Posted : December 14, 2001
Last Update Posted : October 10, 2014
Information provided by (Responsible Party):

December 13, 2001
December 14, 2001
October 10, 2014
October 2002
June 2013   (Final data collection date for primary outcome measure)
  • Maternal and infant response to prescribed interventions [ Time Frame: Throughout study ]
  • Immune and viral parameters of participants taking prescribed interventions [ Time Frame: Throughout study ]
Not Provided
Complete list of historical versions of study NCT00028145 on ClinicalTrials.gov Archive Site
  • Occurrences of genotypic and phenotypic resistance in HIV-infected mothers [ Time Frame: Throughout study ]
  • Clinical, immunological, and virological responses in HIV-infected women [ Time Frame: Throughout study ]
  • Mother-to-child transmission rates of resistance mutations [ Time Frame: Throughout study ]
  • Adherence to ART among HIV-infected pregnant women during pregnancy and postpartum [ Time Frame: Throughout study ]
Not Provided
Not Provided
Not Provided
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
Perinatal Core Protocol

The purpose of this study is to collect and study clinical and laboratory information about a pregnant or new mother and her medical care that will increase our knowledge of the best care for HIV-infected pregnant women and their children.

The rate of transmission of HIV from mothers to their infants has gone down. Specific U.S. Public Health Service guidelines recommend that HIV-infected pregnant women be treated with anti-HIV therapies; but the effectiveness of treatment and safety for the mother and her infant have not been fully examined. This study will monitor the health of women and their infants while they receive anti-HIV therapy. Also, this study will provide information that may be used for future studies.

The current low rate of vertical transmission of HIV in the U.S. limits the number and types of questions concerning transmission risk and pathogenesis that can be addressed by a single clinical trial. Specific U.S. Public Health Service guidelines recommend antiretroviral therapy (ART) during pregnancy to maximize health of women. However, data regarding the effectiveness and safety of and adherence to ART during pregnancy are limited. It is both appropriate and necessary for theInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) to recruit pregnant women into a non-interventional, analytic, epidemiologic study to methodically collect clinical and laboratory data from them and their infants. This way, the IMPAACT can achieve the aims of evaluating management of HIV-infected women during pregnancy and determining the safety and effectiveness of ART and other interventions intended to prevent vertical transmission and/or improve maternal health. In addition, longitudinally collected core protocol data and repository specimens will enable future substudies.

Participants receive no protocol specific treatment or other intervention as part of this study. The study involves the follow-up of HIV-infected women enrolled during pregnancy or at the time of delivery for 6 months postpartum and their infants for the first 6 months of life. There will be 8 study visits for enrolled participants and 6 study visits for infants. Data concerning ART use, adherence to medications, and review of symptoms relevant to side effects and toxicities are collected through administration of questionnaires at all maternal visits. Phlebotomy is conducted to obtain specimens for a repository and for required laboratory tests. During labor and delivery, maternal blood is obtained for lymphocyte subset and viral load assays and for repository storage. Collection of amniotic fluid at the time of cesarean section is encouraged. These collections are submitted to a central repository. Data for the core protocol are abstracted from the infant's medical record at the time of birth and at each postnatal visit.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Blood and amniotic fluid
Probability Sample
Primary care clinics
  • HIV Infections
  • Pregnancy Complications, Infectious
Behavioral: Adherence assessment
Adherence will be assessed using questionnaires at all study visits.
Pregnant, HIV-infected women
Intervention: Behavioral: Adherence assessment

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV infected
  • At least 14 weeks pregnant OR have delivered a liveborn or stillborn infant and are within 14 days of the delivery
  • Currently receiving care at an IMPAACT or other participating site
  • Have a parent or guardian willing to provide signed informed consent, if applicable
  • Mentally capable of giving informed consent to have the infant and self followed at an IMPAACT site

Exclusion Criteria:

  • Intend to end the pregnancy
  • Unable to come for a study visit within 14 days after delivery (if known to be HIV infected prior to delivery) OR within 28 days after delivery (if found to be HIV infected at the time of labor and delivery or within 14 days after delivery)
Sexes Eligible for Study: Female
14 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
U01AI068632 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Chair: Ruth Tuomala, MD Director of Obstetrics and Gynecology, Brigham and Women's Hospital
Study Chair: Gwen Scott, MD Pediatric Infectious Diseases, University of Miami School of Medicine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
October 2014